Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from SNY

5 Best Healthcare Stocks to Buy as a Hedge Against Inflation

The healthcare sector has historically provided a better hedge against inflation than gold because of the inelastic demand for its products and services. Rising healthcare needs of an aging population, integration of advanced technologies, and breakthroughs in clinical trials brighten the sector’s prospects. Therefore, fundamentally-sound and undervalued healthcare stocks Sanofi…

Sanofi-Regeneron's Dupixent Falls Short In Chronic Spontaneous Urticaria Trial

Sanofi-Regeneron's Dupixent Falls Short In Chronic Spontaneous Urticaria Trial

Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have

Hopeful Golden Cross Forms On Sanofi's Chart

Hopeful Golden Cross Forms On Sanofi's Chart

If history is any guide, there may be good fortune ahead for shares of Sanofi (NASDAQ:SNY). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the stock.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Pistons interested in Mitchell Robinson

One note worth keeping in mind with Robinson: The Detroit Pistons are among the teams who've had a degree of interest in the 23-year-old, per SNY sources. Robinson would fit the team's desire to find players on the same timeline as rookie Cade ...

USA Today Sports Media Group

Sanofi Records Q4 Topline, Bottomline Growth As Blockbuster Eczema Drug Soars

Sanofi SA's (NASDAQ: SNY)

What Does Sanofi's Debt Look Like?

Over the past three months, shares of Sanofi (NASDAQ:SNY) increased by 1.88%. Before we understand the importance of debt, let us look at how much debt Sanofi has.

Regeneron, Sanofi Withdraw FDA Application For Libtayo's Expanded Use

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and its partner Sanofi SA (NASDAQ: SNY) have

inkl

Read news from The Economist, FT, and more,
with one subscription

Second Dupixent Phase 3 Trial Confirms Significant Improvements In Inflammatory Skin Disease

Second Dupixent Phase 3 Trial Confirms Significant Improvements In Inflammatory Skin Disease

Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have

1 … 3 4 5 6

People

Mitchell Robinson

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Detroit Pistons

McKesson Corporation

Regeneron Pharmaceuticals Inc

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

243,764 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play